JP2009535016A5 - - Google Patents

Download PDF

Info

Publication number
JP2009535016A5
JP2009535016A5 JP2009504317A JP2009504317A JP2009535016A5 JP 2009535016 A5 JP2009535016 A5 JP 2009535016A5 JP 2009504317 A JP2009504317 A JP 2009504317A JP 2009504317 A JP2009504317 A JP 2009504317A JP 2009535016 A5 JP2009535016 A5 JP 2009535016A5
Authority
JP
Japan
Prior art keywords
sample
mrna
leukocytes
amount
tnfsf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009504317A
Other languages
English (en)
Japanese (ja)
Other versions
JP5027209B2 (ja
JP2009535016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/008597 external-priority patent/WO2007117611A2/en
Publication of JP2009535016A publication Critical patent/JP2009535016A/ja
Publication of JP2009535016A5 publication Critical patent/JP2009535016A5/ja
Application granted granted Critical
Publication of JP5027209B2 publication Critical patent/JP5027209B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009504317A 2006-04-07 2007-04-05 クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強 Expired - Fee Related JP5027209B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79035406P 2006-04-07 2006-04-07
US60/790,354 2006-04-07
PCT/US2007/008597 WO2007117611A2 (en) 2006-04-07 2007-04-05 Enhanced t cell receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with crohn's disease

Publications (3)

Publication Number Publication Date
JP2009535016A JP2009535016A (ja) 2009-10-01
JP2009535016A5 true JP2009535016A5 (enExample) 2010-01-14
JP5027209B2 JP5027209B2 (ja) 2012-09-19

Family

ID=38581650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009504317A Expired - Fee Related JP5027209B2 (ja) 2006-04-07 2007-04-05 クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強

Country Status (6)

Country Link
US (1) US7838239B2 (enExample)
EP (1) EP2005175B1 (enExample)
JP (1) JP5027209B2 (enExample)
CN (1) CN101410714A (enExample)
AT (1) ATE518011T1 (enExample)
WO (1) WO2007117611A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776471B9 (en) * 2004-05-25 2013-12-18 Hitachi Chemical Company, Ltd. Method of measuring cancer susceptibility
JP4772055B2 (ja) * 2004-10-20 2011-09-14 日立化成工業株式会社 ｍＲＮＡの定量により薬剤の投与を選定する方法
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
JP4945554B2 (ja) * 2005-04-28 2012-06-06 ヒタチ ケミカル リサーチ センター インコーポレイテッド 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現
WO2009070442A2 (en) 2007-11-14 2009-06-04 Hitachi Chemical Co. Ltd. Fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes
DE102006051628A1 (de) 2006-11-02 2008-05-08 Daimler Ag Abgasturbolader für eine Brennkraftmaschine
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
EP2056110A1 (en) 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
US20110229471A1 (en) * 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
EP2992792B1 (en) * 2010-11-11 2017-03-15 Nestec S.A. Beverage production machine and rinsing and/or descaling insert
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
EP2734233B1 (en) * 2011-07-18 2017-11-01 Hitachi Chemical Co., Ltd. Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CN103865998B (zh) * 2013-12-16 2016-04-20 周菊华 一种肿瘤免疫治疗效果的基因检测方法
US20150257586A1 (en) * 2014-03-11 2015-09-17 Starbucks Corporation Dba Starbucks Coffee Company Single-serve beverage production machine
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925572A (en) 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4880548A (en) 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
PT938320E (pt) 1996-03-26 2010-09-22 Michael S Kopreski Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro
US5683698A (en) 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US6183951B1 (en) * 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
US20020006613A1 (en) 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies
WO2000076492A1 (en) 1999-06-15 2000-12-21 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US20020048566A1 (en) 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
US7374881B2 (en) * 2000-10-31 2008-05-20 Hitachi Chemical Research Center, Inc. Method for collecting and using nuclear mRNA
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
JP5236856B2 (ja) * 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
CA2467629A1 (en) 2001-11-20 2003-05-30 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6878518B2 (en) 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
US7745180B2 (en) 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
EP1507548B1 (en) 2002-05-27 2014-10-01 CanImGuide Therapeutics AB Method for determining immune system affecting compounds
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
EP1776471B9 (en) 2004-05-25 2013-12-18 Hitachi Chemical Company, Ltd. Method of measuring cancer susceptibility
US8110347B2 (en) 2005-04-15 2012-02-07 Canimguide Therapeutics Ab Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6
JP4945554B2 (ja) 2005-04-28 2012-06-06 ヒタチ ケミカル リサーチ センター インコーポレイテッド 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現
US7935482B2 (en) 2005-09-27 2011-05-03 Source Precision Medicine, Inc. Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease

Similar Documents

Publication Publication Date Title
JP2009535016A5 (enExample)
Esler et al. Aging effects on human sympathetic neuronal function
Tang et al. Up‐regulated miR‐192‐5p expression rescues cognitive impairment and restores neural function in mice with depression via the Fbln2‐mediated TGF‐β1 signaling pathway
Bansi et al. Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training
JP2010539508A5 (enExample)
JP2016513094A5 (enExample)
Paulus et al. The early activation of toll-like receptor (TLR)-3 initiates kidney injury after ischemia and reperfusion
WO2007117611A3 (en) Enhanced t cell receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with crohn's disease
Valekova et al. Revelation of the IFNα, IL-10, IL-8 and IL-1β as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington's disease model
Shrestha et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells
JP2016118568A5 (enExample)
JP2008537474A5 (enExample)
RU2010101909A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
Launay et al. Acceleration-based training: A new mode of training in senescent rats improving performance and left ventricular and muscle functions
Yin et al. Regulation of circulatory muscle-specific MicroRNA during 8 km Run
Allodi et al. Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis
Jafarikhah et al. Effect of functional resistance training on the structure and function of the heart and liver in patients with non-alcoholic fatty liver
Lien et al. Associations among systemic blood pressure, microalbuminuria and albuminuria in dogs affected with pituitary-and adrenal-dependent hyperadrenocorticism
JP2017528114A5 (enExample)
JP2009536021A5 (enExample)
Nair et al. Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP)
JP2013526863A5 (enExample)
Hennen et al. Hypertension promotes bone loss and fragility by favoring bone resorption in mouse models
JP6619611B2 (ja) バイオマーカー、自己免疫性肝炎の診断補助方法、及び、キット
Oliveira Crege et al. Cardiometabolic alterations in Wistar rats on a six-week hyperlipidic, hypercholesterolemic diet